{"code":"D89.832","type":"code","title":"Cytokine release syndrome, grade 2","codeAlso":[],"includes":["defects in the complement system","immunodeficiency disorders, except human immunodeficiency virus [HIV] disease","sarcoidosis"],"modern_v":"official26","codeFirst":["underlying cause, such as:","complications following infusion, transfusion and therapeutic injection (T80.89-)","complications of transplanted organs and tissue (T86.-)"],"excludes1":["hyperglobulinemia NOS (R77.1)","monoclonal gammopathy (of undetermined significance) (D47.2)","autoimmune disease (systemic) NOS (M35.9)","functional disorders of polymorphonuclear neutrophils (D71-)"],"excludes2":["transplant failure and rejection (T86.-)","human immunodeficiency virus [HIV] disease (B20)"],"isBillable":true,"fyEffectivity":{"fy2026":true,"fy2027":true,"billableFy2026":true,"billableFy2027":true},"sibling_codes":["D89","D89.0","D89.1","D89.2","D89.3","D89.4","D89.8","D89.810","D89.811","D89.812","D89.813","D89.831","D89.833","D89.834","D89.835","D89.839","D89.9"],"inclusionTerms":[],"sibling_titles":{"code":"D89.9","title":"Disorder involving the immune mechanism, unspecified","isBillable":true},"useAdditionalCode":["code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)","code to identify associated manifestations"],"clinicalDefinition":"Cytokine release syndrome, grade 2 is a billable ICD-10-CM diagnosis code (D89.832). Includes: defects in the complement system; immunodeficiency disorders, except human immunodeficiency virus [HIV] disease; sarcoidosis. Excludes1 (not coded here): hyperglobulinemia NOS (R77.1); monoclonal gammopathy (of undetermined significance) (D47.2); autoimmune disease (systemic) NOS (M35.9); functional disorders of polymorphonuclear neutrophils (D71-); human immunodeficiency virus [HIV] disease (B20).","officialDefinition":"Cytokine release syndrome, grade 2 is a billable ICD-10-CM diagnosis code (D89.832). Includes: defects in the complement system; immunodeficiency disorders, except human immunodeficiency virus [HIV] disease; sarcoidosis. Excludes1 (not coded here): hyperglobulinemia NOS (R77.1); monoclonal gammopathy (of undetermined significance) (D47.2); autoimmune disease (systemic) NOS (M35.9); functional disorders of polymorphonuclear neutrophils (D71-); human immunodeficiency virus [HIV] disease (B20). Excludes2 (not included here): transplant failure and rejection (T86.-). Code first: underlying cause, such as:; complications following infusion, transfusion and therapeutic injection (T80.89-); complications of transplanted organs and tissue (T86.-). Use additional code: code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5); code to identify associated manifestations.","seventhCharacterInstructions":[],"workflowProtocols":[],"guidelines":{"whenToUse":[],"whenNotToUse":[],"commonBillingMistakes":[],"codeComparisons":[],"documentationChecklist":[]},"domainLandscape":{"summary":"Primary diagnostic domain and clinical landscape evaluation.","keyCategories":[],"diagnosticContinuum":"Progression continuum from acute presentation to resolution."},"children":[],"hierarchy":[],"relatedCodes":[],"relevantCPTCodes":[],"documentationTips":[],"caseStudies":[],"description":"","overview":""}